Nascent Biotech IncOTCQB:NBIO
- LAST PRICE0.0469
- TODAY'S CHANGE (%)0.0001 (0.1067%)
- Bid / Lots0.0410/ 100
- Ask / Lots0.0470/ 100
- Open / Previous Close0.0420 / 0.0469
- Day Range
- 52 Week Range
- Volume50,000
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | NBIO |
|---|---|---|
| 12:30 ET | 42331 | 0.0469 |
| 03:18 ET | 7669 | 0.0469 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Nascent Biotech Inc | 8.1M | -3.9x | --- |
Carmell Corp | 8.2M | -0.3x | --- |
Mustang Bio Inc | 8.3M | -0.1x | --- |
Silexion Therapeutics Corp | 7.8M | -6.2x | --- |
Cyclerion Therapeutics Inc | 7.7M | -0.7x | --- |
Viracta Therapeutics Inc | 8.8M | -0.2x | --- |
Company Information
Nascent Biotech, Inc. is a phase II clinical-stage biopharmaceutical company, which is engaged in developing monoclonal antibodies for the treatment of various cancer types. The Company focuses on biologic drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seeks to further develop those drug candidates for commercial use. It owns a drug candidate, Pritumumab, which the Company is developing as a treatment for epithelial cancers that includes lung, breast, colon, brain, and pancreas. The Company’s initial focus is on the development of Pritumumab as an intravenous treatment of patients with various types of brain cancer, prominently gliomas and malignant astrocytoma. The Company is exploring Pritumumab in its use against viruses. The Company is also engaged in developing a traditional vaccine platform to create vaccines for viral infections.
Contact Information
- Headquarters
- 631 Us Hwy 1, Suite 407NORTH PALM BEACH, FL, United States 33408
- Phone
- 612-961-5656
- Fax
- ---
Executives
- President, Secretary, Director
- Sean Carrick
- Chief Financial Officer, Chief Accounting Officer, Director
- Lowell Holden
- Independent Director
- Douglas Karas
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $8.1M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 172.2M |
Nascent Biotech Inc does not pay a dividend. | |
Beta | -3.26 |
EPS | $-0.01 |
Book Value | $0.00 |
P/E Ratio | -3.9x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
